Circulating Tumour DNA to Guide Treatment of Gastrointestinal Malignancies.

ABSTRACT:

Background

Gastrointestinal cancers are among the most common cancers worldwide and account for a high proportion of cancer-related mortality. Advancements to improve outcomes are constrained by the lack of biomarkers that can offer early diagnostic and prognostic information as traditional serological tumour markers and conventional imaging approaches are not able to provide early information regarding disease recurrence and treatment outcomes. Recent advances in technology have allowed the detection of circulating tumour DNA (ctDNA) in plasma, nucleic acid fragments released into the circulation from primary or metastatic lesions undergoing apoptosis and necrosis. A growing body of evidence has emerged supporting the use of ctDNA in many aspects of cancer care.

Summary

Thi

SUBMITTER: To YH 

PROVIDER: S-EPMC7590785 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature